Analyst Price Target is $16.50
▲ +560.00% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $16.50, with a high forecast of $25.00 and a low forecast of $11.00. The average price target represents a 560.00% upside from the last price of $2.50.
Current Consensus is
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Nkarta. This rating has held steady since September 2023, when it changed from a Moderate Buy consensus rating.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More
